Cargando…

Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges

Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omic...

Descripción completa

Detalles Bibliográficos
Autores principales: Amanatidou, Evropi, Gkiouliava, Anna, Pella, Eva, Serafidi, Maria, Tsilingiris, Dimitrios, Vallianou, Natalia G., Karampela, Irene, Dalamaga, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928742/
https://www.ncbi.nlm.nih.gov/pubmed/35313532
http://dx.doi.org/10.1016/j.metop.2022.100180
_version_ 1784670705732812800
author Amanatidou, Evropi
Gkiouliava, Anna
Pella, Eva
Serafidi, Maria
Tsilingiris, Dimitrios
Vallianou, Natalia G.
Karampela, Irene
Dalamaga, Maria
author_facet Amanatidou, Evropi
Gkiouliava, Anna
Pella, Eva
Serafidi, Maria
Tsilingiris, Dimitrios
Vallianou, Natalia G.
Karampela, Irene
Dalamaga, Maria
author_sort Amanatidou, Evropi
collection PubMed
description Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omicron variant and its unprecedented speed of transmission has posed a new challenge. Overall, Omicron presents increased immune escape, transmissibility, and decreased pathogenicity. Vaccines do not offer a full protection against SARS-CoV-2 acquisition, since “breakthrough” infections may occur in fully vaccinated individuals, who may in turn spread the virus to others. Breakthrough infections may be causally related to the viral profile (viral variant and load, incubation period, transmissibility, pathogenicity, immune evasion), immunity characteristics (mucosal versus systemic immunity, duration of immunity, etc.), host determinants (age, comorbidities, immune status, immunosuppressive drugs) and vaccination properties (platform, antigen dose, dose number, dose interval, route of administration). Determining the rate of breakthrough infections may be challenging and necessitates the conduction of population-based studies regarding vaccine effectiveness as well as neutralizing antibody testing, a surrogate of immune protection. In this review, we analyze the causes of breakthrough infections, their clinical consequences (severity of infection and transmission), methods of determining their incidence as well as challenges and perspectives. Long COVID as well as multi-inflammatory syndrome in adolescents may be significantly reduced in breakthrough infections. The need for universal pancoranavirus vaccines that would aim at protecting against a plethora of SARS-CoV-2 variants as well as emerging variants is discussed. Finally, novel vaccine strategies, such as nasal vaccines, may confer robust mucosal and systemic protection, reducing efficiently transmission.
format Online
Article
Text
id pubmed-8928742
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-89287422022-03-17 Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges Amanatidou, Evropi Gkiouliava, Anna Pella, Eva Serafidi, Maria Tsilingiris, Dimitrios Vallianou, Natalia G. Karampela, Irene Dalamaga, Maria Metabol Open Articles from the Vaccines, Immune Response, Therapeutic Interventions and COVID-19 Special Issue Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omicron variant and its unprecedented speed of transmission has posed a new challenge. Overall, Omicron presents increased immune escape, transmissibility, and decreased pathogenicity. Vaccines do not offer a full protection against SARS-CoV-2 acquisition, since “breakthrough” infections may occur in fully vaccinated individuals, who may in turn spread the virus to others. Breakthrough infections may be causally related to the viral profile (viral variant and load, incubation period, transmissibility, pathogenicity, immune evasion), immunity characteristics (mucosal versus systemic immunity, duration of immunity, etc.), host determinants (age, comorbidities, immune status, immunosuppressive drugs) and vaccination properties (platform, antigen dose, dose number, dose interval, route of administration). Determining the rate of breakthrough infections may be challenging and necessitates the conduction of population-based studies regarding vaccine effectiveness as well as neutralizing antibody testing, a surrogate of immune protection. In this review, we analyze the causes of breakthrough infections, their clinical consequences (severity of infection and transmission), methods of determining their incidence as well as challenges and perspectives. Long COVID as well as multi-inflammatory syndrome in adolescents may be significantly reduced in breakthrough infections. The need for universal pancoranavirus vaccines that would aim at protecting against a plethora of SARS-CoV-2 variants as well as emerging variants is discussed. Finally, novel vaccine strategies, such as nasal vaccines, may confer robust mucosal and systemic protection, reducing efficiently transmission. Elsevier 2022-03-17 /pmc/articles/PMC8928742/ /pubmed/35313532 http://dx.doi.org/10.1016/j.metop.2022.100180 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles from the Vaccines, Immune Response, Therapeutic Interventions and COVID-19 Special Issue
Amanatidou, Evropi
Gkiouliava, Anna
Pella, Eva
Serafidi, Maria
Tsilingiris, Dimitrios
Vallianou, Natalia G.
Karampela, Irene
Dalamaga, Maria
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
title Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
title_full Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
title_fullStr Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
title_full_unstemmed Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
title_short Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
title_sort breakthrough infections after covid-19 vaccination: insights, perspectives and challenges
topic Articles from the Vaccines, Immune Response, Therapeutic Interventions and COVID-19 Special Issue
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928742/
https://www.ncbi.nlm.nih.gov/pubmed/35313532
http://dx.doi.org/10.1016/j.metop.2022.100180
work_keys_str_mv AT amanatidouevropi breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges
AT gkiouliavaanna breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges
AT pellaeva breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges
AT serafidimaria breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges
AT tsilingirisdimitrios breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges
AT vallianounataliag breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges
AT karampelairene breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges
AT dalamagamaria breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges